Close Menu

NEW YORK – HTG Molecular Diagnostics reported after the close of the market on Tuesday that its third quarter revenues grew 15 percent year over year as product-related revenues more than offset a decline in collaborative revenues.

The company also said that it has terminated a companion diagnostic development deal with Qiagen in the wake of that company's discontinuation of next-generation sequencing instruments, causing HTG to also reduce its full-year 2019 revenue guidance.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.